See more : SM Energy Company (0KZA.L) Income Statement Analysis – Financial Results
Complete financial analysis of ViewRay, Inc. (VRAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ViewRay, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Jiangsu Fengshan Group Co.,Ltd (603810.SS) Income Statement Analysis – Financial Results
- CVC Limited (CVC.AX) Income Statement Analysis – Financial Results
- ABB Ltd (ABBN.SW) Income Statement Analysis – Financial Results
- DS Smith Plc (DITHF) Income Statement Analysis – Financial Results
- Weiqiao Textile Company Limited (WQTEF) Income Statement Analysis – Financial Results
ViewRay, Inc. (VRAY)
About ViewRay, Inc.
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.21M | 70.12M | 57.02M | 87.78M | 80.96M | 34.04M | 22.24M | 10.39M | 0.00 | 3.16M |
| Cost of Revenue | 92.16M | 69.78M | 61.08M | 93.26M | 74.36M | 27.71M | 25.87M | 14.54M | 0.00 | 8.19M |
| Gross Profit | 10.05M | 335.00K | -4.06M | -5.48M | 6.60M | 6.33M | -3.63M | -4.15M | 0.00 | -5.03M |
| Gross Profit Ratio | 9.83% | 0.48% | -7.12% | -6.24% | 8.16% | 18.60% | -16.32% | -39.98% | 0.00% | -159.16% |
| Research & Development | 32.43M | 31.85M | 25.01M | 23.79M | 16.52M | 14.71M | 11.44M | 10.45M | 0.00 | 8.78M |
| General & Administrative | 52.44M | 56.09M | 61.73M | 65.72M | 50.11M | 31.38M | 23.50M | 21.69M | 0.00 | 9.51M |
| Selling & Marketing | 30.49M | 16.04M | 15.18M | 25.81M | 15.06M | 8.41M | 5.60M | 5.14M | 0.00 | 3.78M |
| SG&A | 82.93M | 72.14M | 76.91M | 91.52M | 65.18M | 39.79M | 29.10M | 26.82M | 0.00 | 13.29M |
| Other Expenses | 3.17M | -2.17M | 585.00K | 3.20M | 6.39M | -16.77M | -512.00K | -117.00K | 0.00 | 0.00 |
| Operating Expenses | 115.36M | 103.98M | 101.92M | 115.32M | 81.70M | 54.50M | 40.55M | 37.27M | 0.00 | 22.07M |
| Cost & Expenses | 207.52M | 173.77M | 162.99M | 208.58M | 156.05M | 82.21M | 66.41M | 51.82M | 0.00 | 30.26M |
| Interest Income | 1.69M | 13.00K | 791.00K | 1.72M | 8.00K | 5.00K | 2.00K | 2.00K | 0.00 | 4.00K |
| Interest Expense | 5.06M | 4.24M | 3.31M | 4.33M | 7.70M | 7.25M | 5.95M | 3.45M | 0.00 | 97.00K |
| Depreciation & Amortization | 4.85M | -2.16M | 1.38M | 4.92M | 3.50M | 2.20M | 1.71M | 1.26M | 0.00 | 1.15M |
| EBITDA | -100.46M | -105.81M | -104.60M | -115.87M | -68.70M | -62.73M | -44.69M | -41.54M | 0.00 | -26.04M |
| EBITDA Ratio | -98.29% | -150.90% | -183.46% | -132.00% | -84.85% | -184.28% | -200.95% | -399.83% | 0.00% | -824.34% |
| Operating Income | -107.13M | -103.65M | -105.98M | -120.80M | -75.09M | -48.16M | -44.18M | -41.43M | 0.00 | -27.10M |
| Operating Income Ratio | -104.81% | -147.82% | -185.87% | -137.61% | -92.75% | -141.48% | -198.66% | -398.72% | 0.00% | -857.77% |
| Total Other Income/Expenses | -203.00K | -6.40M | -1.93M | 596.00K | -1.30M | -24.01M | -6.46M | -3.57M | 0.00 | -125.00K |
| Income Before Tax | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M | -72.18M | -50.64M | -44.99M | 0.00 | -27.22M |
| Income Before Tax Ratio | -105.01% | -156.94% | -189.26% | -136.93% | -94.36% | -212.02% | -227.71% | -433.05% | 0.00% | -861.73% |
| Income Tax Expense | 203.00K | -3.91M | -2.53M | 2.87M | 1.30M | -9.52M | 3.73M | 1.00K | 0.00 | 0.00 |
| Net Income | -107.53M | -106.13M | -105.38M | -123.07M | -76.40M | -72.18M | -50.64M | -45.00M | 0.00 | -27.22M |
| Net Income Ratio | -105.21% | -151.36% | -184.82% | -140.20% | -94.36% | -212.02% | -227.71% | -433.06% | 0.00% | -861.73% |
| EPS | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| EPS Diluted | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| Weighted Avg Shares Out | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
| Weighted Avg Shares Out (Dil) | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference
DENVER , Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will...
ViewRay® to Present at the Stifel 2022 Healthcare Conference
DENVER , Nov. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in...
ViewRay, Inc. (VRAY) Q3 2022 Earnings Call Transcript
ViewRay, Inc. (NASDAQ:VRAY ) Q3 2022 Results Conference Call November 1, 2022 5:00 PM ET Company Participants Matt Harrison - Director, IR Scott Drake - President & CEO Zach Stassen - CFO Dr. Paul Strong - VP of Clinical Affairs...
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay Announces Third Quarter 2022 Results
DENVER , Nov. 1, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights Total revenue for the third quarter 2022 was approximately $26.5 million, primarily...
MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022 DENVER , Oct. 27, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the final primary endpoint results from the phase III...
ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients
Study's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART DENVER , Oct. 24, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that...
MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022
Clinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies DENVER , Oct. 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian® MRI-Guided Radiation Therapy System will be featured at the 64th Annual Meeting...
ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy
Prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone DENVER , Oct. 18, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the launch of a...
ViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022
DENVER, Oct. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of third quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Tuesday, November 1, 2022, at 5:00 p.m.
Source: https://incomestatements.info
Category: Stock Reports